EUCTR2013-005384-66-GB进行中（未招募）1 期
A phase 3b, open-label pilot study to evaluate the safety and effectiveness of up to four treatment cycles of AA4500 in combination with the ErecAid® Esteem® Manual Vacuum Therapy System in men with Peyronie’s disease. - Safety and Efficacy of AA4500 in men with Peyronie's Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •No subject will be enrolled until all eligibility criteria have been satisfied. To qualify for the study a subject must:
- •1. Be a male =18 years of age
- •2. Have symptom(s) of Peyronie's disease and have evidence of stable disease as determined by the investigator
- •3. Have penile curvature of at least 30° in the dorsal, lateral, or dorsal/lateral plane at screening. It must be possible to delineate the single plane of maximal curvature for evaluation during the study
- •4. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile
- •5. Voluntarily sign and date an informed consent agreement approved by the Independent Ethics Committee (IEC).
- •6. Be able to read, complete and understand the various rating instruments in English.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •A subject will be excluded from study participation if he:
- •1. Has a penile curvature of less than 30° or greater than 90° at the screening visit
- •2. Has any of the following conditions:
- •- Chordee in the presence or absence of hypospadias
- •- Thrombosis of the dorsal penile artery and/or vein
- •- Infiltration by a benign or malignant mass resulting in penile curvature
- •- Infiltration by an infectious agent, such as lymphogranuloma venereum
- •- Ventral curvature from any cause
- •- Presence of an active sexually transmitted disease
- •- Known active hepatitis B or C
- •- Known immune deficiency disease or be positive for human immunodeficiency virus
- •3. Has a history of spontaneous priapism (ie, erection that lasts more than four hours)
- •4. Has previously undergone surgery for Peyronie’s disease
- •5. Fails to have an erection which, in the opinion of the investigator, is sufficient to accurately measure the subject’s penile deformity after administration of prostaglandin E1
- •6. Has a calcified plaque as evident by appropriate radiographic evaluation, penile ultrasound that would prevent proper injection of study medication. Non-contiguous stippling of calcium is acceptable for inclusion provided the calcium deposit does not interfere with the injection of AA4500 into the plaque
- •7. Has an isolated hourglass deformity of the penis
- •8. Has the plaque causing curvature of the penis located proximal to the base of the penis, so that the injection of the local anesthetic would interfere with the injection of AA4500 into the plaque
- •9. Has previously received alternative medical therapies for Peyronie’s disease administered by the intralesional route (including, but not limited to, steroids, verapamil, and the naturally occurring low molecular weight protein, interferon-a2b) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study
- •10. Has received alternative medical therapies for Peyronie’s disease administered by the oral (including, but not limited to, vitamin E [>500 U], potassium aminobenzoate [Potaba], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction medications, or steroidal anti-inflammatory drugs) or topical routes (including, but not limited to, verapamil applied as a cream) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study
- •11. Has had extracorporeal shock wave therapy (ESWT) for the correction of Peyronie’s disease within the 6-month period before screening or plans to have ESWT at any time during the study
- •12. Has used any mechanical type device for correction of Peyronie’s disease within the 2-week period before screening or plans to use any these devices (except for that prescribed by protocol) at any time during the study
- •13. Has used a mechanical device to induce a passive erection within the 2-week period before screening or plans to use any of these devices (except for that prescribed by protocol) at any time during the study
- •14. Has significant erectile dysfunction that has failed to respond to oral treatment with phosphodiesterase type 5 (PDE5) inhibitors
- •15. Has a penile Duplex Doppler ultrasound evaluation at screening that shows compromised penile hemodynamics that in the opinion of the investigator is clinically significant
- •16. Has uncontrolled hypertension, as determined by the investigator
- •17. Has a known
研究者
相似试验
进行中（未招募）
1 期
A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased risk for respiratory syncytial virus disease, compared to older adults 60 years of age and above.Respiratory Syncytial Virus InfectionsMedDRA version: 21.1Level: LLTClassification code: 10035692Term: Pneumonia due to respiratory syncytial virus Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10061603Term: Respiratory syncytial virus infection Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10066741Term: Respiratory syncytial virus infection recurrent Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10035732Term: Pneumonia respiratory syncytial viral Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10052200Term: Respiratory syncytial virus infection NOS Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10038718Term: Respiratory syncytial virus bronchiolitis Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10067384Term: Respiratory syncytial virus pneumonitis Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10069811Term: Respiratory syncytial virus bronchitis Class: 100000004862CTIS2023-510190-34-00GlaxoSmithKline Biologicals1,450
进行中（未招募）
不适用
A phase IIIb, open, controlled study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant booster administration of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine with GSK Biologicals’ Infanrix hexa vaccine in children at 12-15 months of age following a 3-dose primary vaccination in study 10PN-PD-DIT-010 (107017) and to evaluate the impact of pneumococcal vaccination on nasopharyngeal carriage compared to a pneumococcal vaccine unprimed control group receiving GSK iologicals' meningococcal serogroup ACWY conjugate vaccine. - 10PN-PD-DIT-014 BST:010EUCTR2006-001481-17-CZGlaxoSmithKline Biologicals860
进行中（未招募）
1 期
A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).MedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2017-001379-21-GBVertex Pharmaceuticals Incorporated75
进行中（未招募）
1 期
A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).MedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2017-001379-21-IEVertex Pharmaceuticals Incorporated75
进行中（未招募）
1 期
A study to assess the safety and pharmacodynamics of long-term ivacaftor treatment in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).MedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2017-001379-21-DEVertex Pharmaceuticals Incorporated75